openPR Logo
Press release

Key Factors to Fuel Growth of the EpCAM Antagonists Market through 2015 - 2023

12-11-2017 02:19 PM CET | Health & Medicine

Press release from: Transparency Market Research

Key Factors to Fuel Growth of the EpCAM Antagonists Market

Global EpCAM Antagonists Market: Overview

Epithelial cell adhesion molecule (EpCAM), is a cell surface protein or antigen, which is considered an highly expressed element in most of the key cancer types, including prostate, breast, colon, lung, gastric, ovarian, and pancreatic cancer. As a result, EpCAM antagonists are considered as well-established as an ideal therapeutic target and market for cancer of epithelial origin. The growing focus of leading players on research and development activities and technological advancements in the healthcare sector are projected to encourage the growth of the global EpCAM antagonists market throughout the forecast period.

Request Report TOC @ https://www.transparencymarketresearch.com/epcam-antagonists-market.html

The research study offers a detailed analysis of the global EpCAM antagonists market, presenting insights into the important factors that are projected to impact the growth of the overall market in the near future. In addition, the driving factors, restraints, and the promising opportunities in the global EpCAM antagonists market have been highlighted in order to offer a strong understanding of the overall market. The product segmentation, innovations and developments, latest trends, major applications, key regional segments, and the competitive landscape of the global EpCAM antagonists market have been discussed in the research report.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4678

Global EpCAM Antagonists Market: Drivers and Barriers

The tremendously rising prevalence of different types of cancer across the globe is one of the key factors estimated to fuel the growth of the global EpCAM antagonists market throughout the forecast period. In addition, the rising government initiatives and spending on research and development activities for cancer treatment are expected to accelerate the growth of the overall market in the next few years. Furthermore, the constant development in the field of recombinant DNA technology is projected to offer promising opportunities for the key players operating in the global market for EpCAM antagonists.

However, the lack of awareness regarding the availability of advanced therapeutics, especially in developing economies and the high cost of overall cancer treatments are some of the key factors likely to restrict the growth of the global EpCAM antagonists market in the coming few years.

Global EpCAM Antagonists Market: Regional Outlook

The global market for EpCAM antagonists can be classified in terms of geography to offer an in-depth analysis. The key regional segments include Asia Pacific, Europe, North America, and the Rest of the World. Among these, North America is projected to lead the overall market and account for a large share throughout the forecast period. The presence of a large number of leading players operating in this region is one of the major factors estimated to supplement the growth of the EpCAM antagonists market in the next few years.

Furthermore, the rising number of cancer cases in this region is another factor encouraging the growth of the market in the next few years. On the other hand, Asia Pacific is projected to witness significant growth in the coming years.

Companies Mentioned in the Research Report

Some of the key players operating in the EpCAM antagonists market across the globe are Johnson and Johnson, Amgen, Inc., Fresenius Biotech, The University of Hong Kong and American Association for Cancer Research, and Trion Pharma GmbH. The increasing number of players entering the global market and focusing on research and development activities are some of the factors estimated to accelerate the growth of the global EpCAM antagonists market throughout the forecast period.

Furthermore, to offer a clear picture of the competitive landscape of the global EpCAM antagonists market, the research study has provided detailed analysis of the key players in the market. The company profiles, business policies, financial overview, SWOT analysis, recent developments, mergers and acquisitions, and product portfolio have been discussed at length in the scope of the research study.

Pre Book full report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=4678

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. 

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Key Factors to Fuel Growth of the EpCAM Antagonists Market through 2015 - 2023 here

News-ID: 855076 • Views:

More Releases from Transparency Market Research

Global Opioid Induced Constipation Treatment Market Set to Reach USD 5.2 Billion by 2036, Driven by Rising Opioid Use and Targeted Therapies
Global Opioid Induced Constipation Treatment Market Set to Reach USD 5.2 Billion …
The global opioid induced constipation (OIC) treatment market is witnessing steady and sustained growth as healthcare systems worldwide place increasing emphasis on comprehensive pain management and supportive care. Valued at US$ 2.9 billion in 2025, the market is projected to reach US$ 5.2 billion by 2036, expanding at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2036. Growth is primarily fueled by the rising prevalence of chronic
Pneumatic Flux Chipper Market Expanding at 7.4% CAGR Through 2036 - By Product Type / By Impact Frequency | China • India • Japan • U.S.
Pneumatic Flux Chipper Market Expanding at 7.4% CAGR Through 2036 - By Product T …
The global Pneumatic Flux Chipper Market is set to witness sustained and resilient growth over the next decade, underpinned by expanding heavy manufacturing activities, rising welding and fabrication demand, and continuous investments in industrial infrastructure across emerging and developed economies. According to the latest industry analysis, the market was valued at US$ 760.5 Mn in 2025 and is projected to reach US$ 1,680.8 Mn by 2036, expanding at a compound
AI in Automotive Market Outlook 2036: Global Industry to Surge from US$ 19.8 Billion in 2025 to US$ 244.4 Billion at 27% CAGR
AI in Automotive Market Outlook 2036: Global Industry to Surge from US$ 19.8 Bil …
The AI in automotive market is entering a phase of exponential expansion, supported by rapid digitization of vehicles, growing safety mandates, and consumer demand for intelligent mobility. The global market was valued at US$ 19.8 Bn in 2025 and is projected to reach US$ 244.4 Bn by 2036, registering a remarkable CAGR of 27% from 2026 to 2036. This growth trajectory reflects the transition of automobiles from mechanically driven products to
Hypodermic Needles Market to Reach US$ 7.9 Billion by 2036 on Rising Injectable Drug Demand
Hypodermic Needles Market to Reach US$ 7.9 Billion by 2036 on Rising Injectable …
The global hypodermic needles market was valued at approximately US$ 4.2 billion in 2025 and is projected to reach around US$ 7.9 billion by 2036, expanding at a CAGR of nearly 5.8% from 2026 to 2036, driven by the rising prevalence of diabetes, cancer, and chronic diseases, growing demand for injectable drugs and biologics, and the expansion of global vaccination and immunization programs; increasing adoption of safety-engineered and disposable needles,

All 5 Releases


More Releases for EpCAM

Malignant Ascites Market Size (7MM) was ~USD 1,990 million in 2020, which is ant …
DelveInsight's "Malignant Ascites Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Malignant Ascites, historical and forecasted epidemiology as well as the Malignant Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover Key Insights into the Malignant Ascites Market with DelveInsight's In-Depth Report @ Malignant Ascites Market Size- https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Malignant Ascites Market Report • In December 2025,
EpCAM Antibody Market is expected to reach USD 2.5 billion by 2034, growing at a …
" The global EpCAM antibody market is valued at approximately $1.2 billion in 2024 and is projected to reach around $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.6% during the 2025-2034 period. The market is currently characterized by rapid advancements in targeted therapies and increasing research activities focusing on EpCAM's role in cancer diagnostics and therapeutics." Exactitude Consultancy., Ltd. released a research report titled "EpCAM
Malignant Ascites Market Growth to Accelerate in Forecast Period (2024-2034) | e …
DelveInsight's "Malignant Ascites Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Malignant Ascites, historical and forecasted epidemiology as well as the Malignant Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover Key Insights into the Malignant Ascites Market with DelveInsight's In-Depth Report @ Malignant Ascites Market Size- https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Malignant Ascites Market
Malignant Ascites Therapeutics Market Size in the 7MM was ~ USD 1990 Million in …
DelveInsight's "Malignant Ascites Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Malignant Ascites, historical and forecasted epidemiology as well as the Malignant Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover Key Insights into the Malignant Ascites Market with DelveInsight's In-Depth Report @ [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr] Key Takeaways from the Malignant Ascites Market Report * Among the 7MM, the United
03-01-2017 | Health & Medicine
TMR
Rising Government Initiatives and Spending on Research and Development Activitie …
Epithelial cell adhesion molecule (EpCAM), is a cell surface protein or antigen, which is considered an highly expressed element in most of the key cancer types, including prostate, breast, colon, lung, gastric, ovarian, and pancreatic cancer. As a result, EpCAM antagonists are considered as well-established as an ideal therapeutic target and market for cancer of epithelial origin. The growing focus of leading players on research and development activities and technological
02-03-2017 | Health & Medicine
TMR
EpCAM Antagonists Market - Driving Factors, Restraints and the Promising Opportu …
Epithelial cell adhesion molecule (EpCAM), is a cell surface protein or antigen, which is considered an highly expressed element in most of the key cancer types, including prostate, breast, colon, lung, gastric, ovarian, and pancreatic cancer. As a result, EpCAM antagonists are considered as well-established as an ideal therapeutic target and market for cancer of epithelial origin. The growing focus of leading players on research and development activities and technological